Abstract: In an embodiment, a method includes receiving user interface information having event registrations for a user interface to be displayed on a display of a system, partitioning the display into an unused display area and an active display area based on the event registrations, and power managing the unused display area while maintaining the active display area fully powered. Other embodiments are described and claimed.

Abstract: Embodiments of the invention provide an array substrate, a manufacturing method thereof and a display device. The array substrate comprises: a base substrate; a gate line and a gate electrode formed on the base substrate; a gate insulating layer formed on the gate line and the gate electrode; a source electrode, a drain electrode and a pixel electrode formed on the gate insulating layer, wherein the pixel electrode is directly connected to the drain electrode; and an active layer formed on the gate insulating layer, the source electrode and the drain electrode.

Abstract: The present invention provides the glucagon-like peptide-1 receptor agonists. It is indicated that the agonists have good binding capability to glucagon-like peptide-1 receptor by pharmacological tests. The present invention also provides the preparation of the agonists.

Abstract: The present invention provides small molecule compounds of bisheterocycle in tandem having the structural formula of P1-P2, and the use thereof as well as a composition containing the compounds, each of P1 and P2 is an unsaturated 5-member heterocyclic ring having one or two heteroatoms. This compound may effectively inhibit the replication of influenza virus, the DNA replication of hepatitis B virus (HBV), and the formation of HBsAg and HBeAg. These compounds can be used for the preparation of a medicament for viral diseases, and may overcome the limitations of the known nucleosides drugs, including cytotoxicity, the requirement of other drugs having different structures for against the drug-resistant virus variants induced by long-term therapy. The structure of the compounds according to the invention is relatively simple and easy to be prepared.

Abstract: The present invention provides patterned leads for a wafer level chip size package and methods for fabricating the same. The patterned leads include connection leads and solder pads. In designing, a compensation pattern is disposed on the connection lead or on the solder pad, so as to increase the distance between the connection lead and the solder pad. The present invention meets a tendency of increasing quantity per area of peripheral arrayed compatible pads and solder bumps on a semiconductor chip, and also saves more space for layout of leads on the chip bottom surface so as to avoid potential short circuit in between which happens in increasing probability with increasing quantity per area on the condition of the lead and the solder bump.

Abstract: The present invention provides a wafer level optical waveguide and a method for manufacturing the same, wherein it can be realized by employing manufacture process for semiconductor integrated circuits to manufacture a micron optical waveguide with a smooth interface, uniform thickness and a mirror-like end with any angle, and to remarkably reduce its manufacture cost at the meantime.

Abstract: The present invention provides a wafer level optical waveguide and a method for manufacturing the same, wherein it can be realized by employing manufacture process for semiconductor integrated circuits to manufacture a micron optical waveguide with a smooth interface, uniform thickness and a mirror-like end with any angle, and to remarkably reduce its manufacture cost at the meantime.

Abstract: The present invention provides small molecule compounds of bisheterocycle in tandem having the structural formula of P1-P2, and the use thereof as well as a composition containing the compounds, each of P1 and P2 is an unsaturated 5-member heterocyclic ring having one or two heteroatoms. This compound may effectively inhibit the replication of influenza virus, the DNA replication of hepatitis B virus (HBV), and the formation of HBsAg and HBeAg. These compounds can be used for the preparation of a medicament for viral diseases, and may overcome the limitations of the known nucleosides drugs, including cytotoxicity, the requirement of other drugs having different structures for against the drug-resistant virus variants induced by long-term therapy. The structure of the compounds according to the invention is relatively simple and easy to be prepared.

Abstract: The present invention provides the glucagon-like peptide-1 receptor agonists. It is indicated that the agonists have good binding capability to glucagon-like peptide-1 receptor by pharmacological tests. The present invention also provides the preparation of the agonists.